Transitioning from a development-stage to a commercial-stage company by targeting the premium, direct-pay concierge and preventive cardiology segments. The company has established flagship commercial sites across New York, Dallas, South Florida, and Southern California through partnerships with ClearCardio and Atelier Health.

Expected impact: Establishes an initial foothold in the structured direct-pay healthcare segment (representing ~5 million U.S. patients), validates the subscription-based pricing model, and builds a repeatable commercial framework.

Developing and clinically validating heart attack (acute coronary syndrome) detection capabilities on the HeartBeam platform, targeting a market of over 20 million high-risk patients in the U.S.

Expected impact: Expands FDA cleared indications from arrhythmia assessment to acute coronary syndrome/heart attack detection, significantly increasing the addressable market.

Developing a novel, continuous 1-lead and on-demand 12-lead ECG patch monitor to target the $2 billion patch monitor market.

Expected impact: Provides a clinical-grade 12-lead solution in a market currently dominated by 1- to 3-lead devices, capturing substantial physician interest and market share.

Developing, training, and validating a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform, leveraging longitudinal, real-world 12-lead ECG data collected at home.

Expected impact: Enables personalized cardiac AI models for wellness, condition-focused assessments, and chronic disease management, shifting the platform from symptom monitoring to disease management.